Co-engagement of TIGIT+ immune cells to PD-L1+ tumours by a bispecific antibody potentiates T-cell response and tumour control
Cui, X.; Yu, H.; Zhu, X.; Xu, J.; Wei, X.; Chen, S.; Wang, Y.; Chen, X.; Feng, Y.; Ren, X.; Fei, L.; Xie, B.; Li, M.; Li, X.; Jia, H.; Xie, S.; Chen, L.; Cheng, Y.; Zhang, L.; Li, H.; Zhu, X.; Zhan, Y.
Show abstract
Co-targeting PD-1/PD-L1 and TIGIT/CD226 is being pursued to broaden the efficacy of current immunotherapy. Here we demonstrate that a bispecific antibody (BsAb) targeting PD-L1 and TIGIT, HB0036, shows major advantages over the combination of the two parental monoclonal Abs (mAbs). We demonstrated that HB0036 co-engages PD-L1+ tumour cells and TIGIT+ T cells, and thereby upregulates CD226 on T cells and induces a greater T-cell proliferative response compared to the combination of the parental antibodies in vitro. In vivo, HB0036 recruits greater amounts of TIGIT antibody in PD-L1+ tumours but not in PD-L1- tumours, compared with therapy using the two parental antibodies. We also observed improved tumour control and favourable immunological signatures with HB0036 in syngeneic and xenograft tumour models. Collectively, these findings demonstrate that bispecific antibodies targeting PD-L1 and TIGIT offer superior benefits in cancer immunotherapy compared with therapy using the two parental antibodies. Based on these studies, a phase I clinical trial with HB0036 has been initiated in patients with solid tumours (NCT05417321).
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling. 96%
- Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma 96%
- Overcoming Tumor Heterogeneity by Ex Vivo Arming of T Cells Using Multiple Bispecific Antibodies 96%
Similar papers in this journal
- Exploration of T-cell immune responses by expression of a dominant-negative SHP1 and SHP2 95%
- Bcl6 Preserves the Suppressive Function of Regulatory T Cells during Tumorigenesis 95%
- Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression 95%
Similar papers in this journal
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 96%
- Antibody Targeting of B7-H4 Enhances the Immune Response in Urothelial Carcinoma 95%
- CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade 95%
Similar papers in this journal
- PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma 97%
- Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory 96%
- Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination With Nivolumab 96%
Similar papers in this journal
- Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction 97%
- Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy 96%
- NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.